J Korean Med Sci.  2005 Aug;20(4):607-611. 10.3346/jkms.2005.20.4.607.

Polymorphism of Matrix Metalloproteinase-3 Promoter Gene as a Risk Factor for Coronary Artery Lesions in Kawasaki Disease

• Park JA
• Shin KS
• Kim YW

• KMID: 1712741
• DOI: http://doi.org/10.3346/jkms.2005.20.4.607

Abstract

Kawasaki disease (KD) is a major cause of acquired coronary artery diseases in childhood. The serum levels of matrix metalloproteinase (MMP)-3 and MMP-9 in KD have been reported to be significantly higher than other diseases. Several studies have demonstrated that MMP-3 5A/6A polymorphism and MMP-9 C-1562T polymorphism modify each transcriptional activity in allele specific manner. We hypothesized that these polymorphisms may play a role as a risk factor for development of coronary artery lesions (CAL) in KD. Eighty-three patients, diagnosed with KD in Cheju National University Hospital from January 2000 to February 2004, were divided into two groups according to the presence of CAL. Genotyping of MMP-3 and MMP-9 gene polymorphisms were determined by restriction fragment length polymorphism. With regard to MMP-3 gene polymorphism, the KD with CAL group had a higher frequency of 6A/6A genotype than control group (p=0.0127) and the KD without CAL group (p=0.0036). However, no significant differences in the allele and genotype distributions of the MMP-9 polymorphism were observed. These findings suggest that MMP-3 6A/6A genotype may be an independent risk factor for CAL formation in KD.

Keyword

Matrix Metalloproteinases; Kawasaki Disease; Mucocutaneous Lymph Node Syndrome; Coronary Vessels; Polymorphism; Genetic

MeSH Terms

Adolescent
Adult
Aged
Alleles
Child
Child, Preschool
Coronary Arteriosclerosis/enzymology/etiology/*genetics
Female
Gelatinase B/genetics
Gene Frequency
Genotype
Humans
Infant
Male
Middle Aged
Mucocutaneous Lymph Node Syndrome/*complications
*Polymorphism, Genetic
Promoter Regions (Genetics)/*genetics
Research Support, Non-U.S. Gov't
Risk Factors
Stromelysin 1/*genetics

Reference

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children: Clinical observation of 50 cases. Jpn J Allergy. 1967. 16:178–222.

2. Yanagihara R, Todd JK. Acute febrile mucocutaneous lymph node syndrome. Am J Dis Child. 1980. 134:603–614.

3. Kato H, Ichinose E, Yoshioka F, Takechi T, Matsunaga S, Suzuki K, Rikitake N. Fate of coronary aneu-rysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol. 1982. 49:1758–1766.

4. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol. 1990. 56:29–36.

5. Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, Sasaki N, Asano H, Kyo S, Yokote Y. Circulating matrix metalloproteinase and their inhibitors in patients with Kawasaki disease. Circulation. 2001. 104:860–863.

6. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in human stromelysin gene promoter is associated with progression of atherosclerosis. Br Heart J. 1995. 73:209–215.

7. Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet. 1999. 105:418–423.

8. Yoon S, Tromp G, Vongpunsawad S, Ronkainen A, Juvonen T, Kuivaniemi H. Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Commun. 1999. 265:563–568.

9. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, Arveiler D, Luc G, Cambien F, Hamsten A, Watkins H, Henney AM. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999. 99:1788–1794.

10. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996. 271:13055–13060.

11. Shimajiri S, Arima N, Tanimoto A, Murata Y, Hamada T, Wang KY, Sasaguri Y. Shortened microsatellite d(CA) 21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett. 1999. 455:70–74.

12. Japanese Kawasaki Disease Research Committee. Diagnostic guidelines of Kawasaki disease. 1984. 4th ed. Tokyo: Japan Kawasaki Disease Research Committee.

13. Nakano H, Ueda K, Saito A, Nojima K. Repeated quantitative angiograms in coronary arterial aneurysm in Kawasaki disease. Am J Cardiol. 1985. 56:846–851.

14. Dunleavey L, Beyzade S, Ye S. Rapid genotype analysis of the stromelysin gene 5A/6A polymorphism. Atherosclerosis. 2000. 151:587–589.

15. Kim JS, Park HY, Kwon JH, Im EK, Choi DH, Jang YS, Cho SY. The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med J. 2002. 43:473–481.

16. Fujiwara T, Fujiwara H, Hamashima Y. Frequency and size of coronary arterial aneurysm at necropsy in Kawasaki disease. Am J Cardiol. 1987. 59:808–811.

17. Delclaux C, Delacourt C, D'ortho MP, Boyer V, Lafuma C, Harf A. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across the basement membrane. Am J Respir Cell Mol Biol. 1996. 14:288–295.

18. Senzaki H, Kobayashi T, Nagasaka H, Nakano H, Kyo S, Yokote Y, Sasaki N. Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy. Pediatr Res. 2003. 53:983–988.

19. Cho AR, Hong YM. Matrix metalloproteinase, tissue inhibitors and cytokines in patients with Kawasaki disease. Korean J Pediatr. 2004. 47:656–664.

20. Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbecque N, Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol. 2002. 40:43–48.

21. Humphries S, Bauters C, Meirhaeghe A, Luong L, Bertrand M, Amouyel P. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur Heart J. 2002. 23:721–725.

22. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biology. 2000. 19:623–629.

23. Jones GT, Phillips VL, Harris EL, Rossaak JI, van Rij AM. Functional matrix metalloproteinase-9 polymorphism (c-1562T) associated with abdominal aortic aneurysm. J Vasc Surg. 2003. 38:1363–1367.

24. Uehara R, Yashiro M, Hayasaka S, Oki I, Nakamura Y, Muta H, Ishii M, Matsuishi T, Sonobe T, Yanagawa H. Serum alanine aminotransferase concentrations in patients with Kawasaki disease. Pediatr Infect Dis J. 2003. 22:839–842.

25. Wang J, Warzecha D, Wilcken D, Wang XL. Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin Sci. 2001. 101:87–92.

26. Nelissen I, Vandenbroeck K, Fiten P, Hillert J, Olsson T, Marrosu MG, Opdenakker G. Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. J Neuroimmunol. 2000. 105:58–63.

27. Cho HJ, Chae IH, Park KW, Ju JR, Oh S, Lee MM, Park YB. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J Hum Genet. 2002. 47:88–91.